Modified-Release Minoxidil Formulation for Sustained Oral Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for hair loss, such as topical minoxidil, often result in rapid absorption and short half-life, leading to suboptimal therapeutic effects and potential adverse effects due to peak serum concentrations.
Innovation Solution
A modified release formulation of minoxidil or its pharmaceutically acceptable salt, designed for oral administration, which releases 50% to 98% of the daily dose within 12 hours, with a Tmax of 30 to 360 minutes and Cmax of 0.25 ng/ml to 20 ng/ml, providing sustained drug release and minimizing peak serum concentrations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If topical minoxidil is used for hair loss treatment, then hair regrowth effect is achieved, but rapid absorption occurs leading to short half-life and suboptimal therapeutic effects
Solution Approach 1:
The patent segments the minoxidil delivery system into multiple components: a core containing minoxidil and a coating layer with controlled porosity. This segmentation allows the drug to be released in a controlled manner rather than all at once, extending the duration of action and maintaining consistent therapeutic levels.
Solution Approach 2:
The patent introduces an intermediary controlled-release mechanism (the coating layer with specific porosity) between the minoxidil and the biological system. This intermediary controls the release rate, preventing rapid absorption and extending half-life while maintaining reliable therapeutic effects.
2Reliability
If topical minoxidil is applied, then therapeutic effect is achieved, but peak serum concentrations cause adverse effects
Solution Approach 1:
The patent converts the harmful rapid absorption into a benefit by using the coating layer's porosity to control release. The same property that could allow rapid entry is instead used to create a sustained release profile, turning the potential harm of peak concentrations into the benefit of stable therapeutic levels.
Solution Approach 2:
The patent changes the release rate parameter of minoxidil by adjusting the coating layer porosity. This parameter change transforms the concentration-time profile from a sharp peak to a sustained plateau, maintaining therapeutic efficacy while eliminating adverse effects from peak concentrations.
3Speed
If immediate release formulation is used, then rapid drug availability is achieved, but therapeutic duration is insufficient for hair regrowth
Solution Approach 1:
The patent creates a dynamic release system where the coating layer gradually releases minoxidil over time. The porosity of the coating allows initial rapid release for quick availability, then transitions to slower release for extended duration, providing both speed and sustainability.
Solution Approach 2:
The patent implements periodic action through the controlled-release coating that releases minoxidil in a sustained manner over multiple days. This periodic release pattern ensures continuous therapeutic presence in the system, extending duration while maintaining adequate drug availability.
Data Source
AI summary
The compositions and methods provided herein include a pharmaceutical formulation for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical formulations for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof and one or more additional active agents. Also provided herein are methods of treating hair loss by administering to a subject in need thereof a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Further provided herein is a kit including a slow modified release vehicle comprising oral minoxidil or a pharmaceutically acceptable salt thereof.